Legend Biotech Corp. (LEGN)
19.98
-0.52
(-2.54%)
USD |
NASDAQ |
Aug 28, 11:59
Legend Biotech Cash from Operations (Quarterly) : -20.87M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.87M |
| March 31, 2026 | -85.35M |
| December 31, 2025 | -105.64M |
| September 30, 2025 | 28.91M |
| June 30, 2025 | -13.33M |
| March 31, 2025 | -103.75M |
| December 31, 2024 | -82.09M |
| September 30, 2024 | -75.05M |
| June 30, 2024 | -0.397M |
| March 31, 2024 | 16.18M |
| December 31, 2023 | -93.24M |
| September 30, 2023 | -58.48M |
| June 30, 2023 | -91.69M |
| March 31, 2023 | -141.05M |
| Date | Value |
|---|---|
| December 31, 2022 | -48.78M |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | -78.69M |
| December 31, 2021 | -68.56M |
| September 30, 2021 | -44.39M |
| June 30, 2021 | -57.67M |
| March 31, 2021 | -26.74M |
| December 31, 2020 | -56.16M |
| September 30, 2020 | -64.38M |
| June 30, 2020 | -56.88M |
| March 31, 2020 | -45.80M |
| December 31, 2019 | -59.99M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 3.436B |
| Dianthus Therapeutics, Inc. | -48.98M |
| Gilead Sciences, Inc. | 3.573B |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Arbutus Biopharma Corp. | -5.952M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -120.10M |
| Cash from Financing (Quarterly) | 168.05M |
| Free Cash Flow | -264.16M |
| Free Cash Flow Per Share (Quarterly) | -0.2141 |
| Free Cash Flow to Equity (Quarterly) | 69.62M |
| Free Cash Flow to Firm (Quarterly) | -38.01M |
| Free Cash Flow Yield | -7.07% |